已发表论文

本文章已被撤回:细胞分化剂 2(CDA-2)通过 miR-124/MAPK1 抑制 Saos-2 细胞的生长和迁移

 

Authors Li Q, Li G, Liu C, Chen N, Deng B, Xie Y

Received 8 February 2020

Accepted for publication 15 May 2020

Published 15 June 2020 Volume 2020:12 Pages 4541—4548

DOI https://doi.org/10.2147/CMAR.S248851

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Ahmet Emre Eskazan

***本文章已被撤回***



Background: CDA-2 (cell differentiation agent 2), isolated from healthy human urine, exerts antitumor effects in multiple types of cancer cells. However, its role in osteosarcoma has not been studied.
Methods: The MTT assay was used to examine the cell proliferation rate. A colony formation assay was used to examine cell growth. The Transwell assay was used to examine cell migration ability. A real-time PCR assay was used to examine the expression levels of miR-124 and MAPK1. A Western blot assay was used to examine protein expression levels. MAPK1 was selected as a possible target of miR-124, and the targeting relationship was examined by a luciferase reporter assay.
Results: We revealed that CDA-2 decreased the growth, migration and invasion ability of the osteosarcoma cell line Saos-2. Further study revealed that CDA-2 elevated the expression level of miR-124. MAPK1 was identified as a downstream target of miR-124. Knockdown of miR-124 or overexpression of MAPK1 counteracted CDA-2’s effects on cell growth and invasion.
Conclusion: Our data revealed that the miR-124/MAPK1 axis mediated CDA-2’s function in Saos-2 cells. CDA-2 can be used as a new treatment strategy for osteosarcoma.
Keywords: cell differentiation agent 2, osteosarcoma, miR-124, MAPK1




Figure 4 miR-124/MAPK1 pathway mediated CDA-2’s anti-tumor effect...